News Omni Bio Pharmaceutical, Inc.

Equities

OMBP

US68216L1008

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+66.67%	+233.33%

2016	Omni Bio Pharmaceutical, Inc. cancelled the transaction announced on March 16, 2015	CI
2015	Omni Bio Pharmaceutical, Inc. Announces Management Changes	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Omni Bio Pharmaceutical, Inc. cancelled the transaction announced on March 16, 2015	16-03-15	CI
Omni Bio Pharmaceutical, Inc. Announces Management Changes	15-06-25	CI
Omni Bio Pharmaceutical, Inc. announced a financing transaction	15-03-15	CI
Omni Bio Pharmaceutical, Inc. announced that it has received $2.3 million in funding from Bohemian Investments	15-03-12	CI
Omni Bio Pharmaceutical, Inc. Announces Clinical Data for Use of Alpha-1 Antitrypsin in Steroid-Resistant Graft Versus Host Disease	14-12-09	CI
Omni Bio Pharmaceutical, Inc. Announces Presentation of Phase 1/2 Clinical Data for AAT at American Heart Association Scientific Sessions	14-11-19	CI
Omni Bio Successfully Completes Cell Line Optimization for Novel Recombinant Biologic	14-11-18	CI
Omni Bio Pharmaceutical, Inc. Appoints Jack Riccardi as Chief Financial Officer, with Effect from September 1, 2014	14-08-14	CI
Omni Bio Pharmaceutical, Inc. Auditor Raises 'Going Concern' Doubt	14-06-15	CI
Omni Bio Pharmaceutical, Inc. Appoints Bruce D. Forrest as Chief Development Officer	14-05-01	CI
Omni Bio Pharmaceutical, Inc. Announces Publication of Its Pilot Study of Alpha-1 Antitrypsin in Type 1 Diabetes	14-04-30	CI
Gallus BioPharmaceuticals, LLC Enters Cell Line Optimization and Manufacturing Agreement with Omni Bio Pharmaceutical, Inc	14-04-29	CI
Omni Bio Pharmaceutical, Inc. announced that it expects to receive $2 million in funding from Bohemian Investments.	14-04-14	CI
Robert C. Ogden Tenders Resignation as Chief Financial Officer of Omni Bio Pharmaceutical, Inc., Effective March 28, 2014	14-03-07	CI
Omni Bio Pharmaceutical, Inc. Receives Notice of Allowance for the Use of Alpha-1 Antitrypsin to Reduce Risk of Non-Organ Transplant Rejection and to Treat Graft Versus Host Disease	13-11-26	CI
Omni Bio Pharmaceutical, Inc. Announces Reduction in Inflammatory Myocardial Injury with its Lead Recombinant Molecule	13-11-20	CI
Omni Bio Pharmaceutical, Inc. Receives Notice of Allowance for its First U.S. Patent Action for Recombinant Alpha-1 Antitrypsin Molecule	13-11-06	CI
Omni Bio Pharmaceutical, Inc. Announces Board Changes	13-08-15	CI
Omni Bio Pharmaceutical, Inc. Appoints Sandra J. Wrobel to its Board of Directors	13-07-17	CI
Omni Bio Pharmaceutical, Inc. Announces Resignation of Michael Iseman as Member of the Board of Directors	13-07-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Omni Bio Pharmaceutical, Inc.

Equities

OMBP

US68216L1008

Summary

Filters